CA3213383A1 - Pharmaceutical compositions comprising zolmitriptan - Google Patents
Pharmaceutical compositions comprising zolmitriptan Download PDFInfo
- Publication number
- CA3213383A1 CA3213383A1 CA3213383A CA3213383A CA3213383A1 CA 3213383 A1 CA3213383 A1 CA 3213383A1 CA 3213383 A CA3213383 A CA 3213383A CA 3213383 A CA3213383 A CA 3213383A CA 3213383 A1 CA3213383 A1 CA 3213383A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- zolmitriptan
- points
- hours
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163165938P | 2021-03-25 | 2021-03-25 | |
| US63/165,938 | 2021-03-25 | ||
| US202263306377P | 2022-02-03 | 2022-02-03 | |
| US63/306,377 | 2022-02-03 | ||
| PCT/US2022/021738 WO2022204399A1 (en) | 2021-03-25 | 2022-03-24 | Pharmaceutical compositions comprising zolmitriptan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3213383A1 true CA3213383A1 (en) | 2022-09-29 |
Family
ID=83397893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3213383A Pending CA3213383A1 (en) | 2021-03-25 | 2022-03-24 | Pharmaceutical compositions comprising zolmitriptan |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240189240A1 (https=) |
| EP (1) | EP4313037A4 (https=) |
| JP (1) | JP2024512069A (https=) |
| KR (1) | KR20240004330A (https=) |
| AU (1) | AU2022246101A1 (https=) |
| BR (1) | BR112023019407A2 (https=) |
| CA (1) | CA3213383A1 (https=) |
| IL (1) | IL307194A (https=) |
| MX (1) | MX2023011240A (https=) |
| WO (1) | WO2022204399A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117017983A (zh) * | 2023-10-09 | 2023-11-10 | 中山大学 | 曲普坦类药物在制备抗感染药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3090743A1 (en) * | 2008-01-09 | 2016-11-09 | Charleston Laboratories, Inc. | Pharmaceutical compositions for treating headache and eliminating nausea |
| US20100179202A1 (en) * | 2009-01-14 | 2010-07-15 | Ajanta Pharma Limited. | Orally disintegrating composition of zolmitriptan |
| CN104411301B (zh) * | 2012-04-18 | 2018-02-06 | 康特拉医药公司 | 适于改善运动障碍治疗的口服药物配方 |
| KR20160117596A (ko) * | 2014-02-07 | 2016-10-10 | 오스펙스 파마슈티칼스, 인코포레이티드 | 신규 제약 제제 |
| HUE059559T2 (hu) * | 2015-02-25 | 2022-12-28 | Univ California | 5HT agonisták az epilepsziás rendellenességek kezelésére |
| ES3056138T3 (en) * | 2019-10-23 | 2026-02-18 | Maplight Therapeutics Inc | Methods of treating the symptoms of autism spectrum disorder |
-
2022
- 2022-03-24 US US18/552,420 patent/US20240189240A1/en active Pending
- 2022-03-24 EP EP22776651.6A patent/EP4313037A4/en active Pending
- 2022-03-24 CA CA3213383A patent/CA3213383A1/en active Pending
- 2022-03-24 IL IL307194A patent/IL307194A/en unknown
- 2022-03-24 BR BR112023019407A patent/BR112023019407A2/pt unknown
- 2022-03-24 WO PCT/US2022/021738 patent/WO2022204399A1/en not_active Ceased
- 2022-03-24 JP JP2023558740A patent/JP2024512069A/ja active Pending
- 2022-03-24 AU AU2022246101A patent/AU2022246101A1/en active Pending
- 2022-03-24 KR KR1020237036000A patent/KR20240004330A/ko active Pending
- 2022-03-24 MX MX2023011240A patent/MX2023011240A/es unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117017983A (zh) * | 2023-10-09 | 2023-11-10 | 中山大学 | 曲普坦类药物在制备抗感染药物中的应用 |
| CN117017983B (zh) * | 2023-10-09 | 2023-12-22 | 中山大学 | 曲普坦类药物在制备抗感染药物中的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023019407A2 (pt) | 2023-11-28 |
| AU2022246101A1 (en) | 2023-10-12 |
| KR20240004330A (ko) | 2024-01-11 |
| MX2023011240A (es) | 2024-01-12 |
| JP2024512069A (ja) | 2024-03-18 |
| WO2022204399A1 (en) | 2022-09-29 |
| EP4313037A4 (en) | 2025-02-26 |
| US20240189240A1 (en) | 2024-06-13 |
| IL307194A (en) | 2023-11-01 |
| EP4313037A1 (en) | 2024-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5968300B2 (ja) | 高用量、水溶性及び吸湿性薬剤基質用の制御放出性剤形 | |
| US7915247B1 (en) | Methods of use of fenofibric acid | |
| KR100882707B1 (ko) | 라모트리진을 포함하는 서방형 제제 | |
| RU2298402C2 (ru) | Твердая лекарственная форма тербинафина для перорального введения | |
| US10881618B2 (en) | Compositions for treatment of attention deficit hyperactivity disorder | |
| MX2013010920A (es) | Metodos y composiciones para el tratamiento de transtorno por deficit de atencion. | |
| JP2022104916A (ja) | 自己調節性の浸透性胃保持性薬物送達システム | |
| KR102486126B1 (ko) | 알펠리십을 포함하는 제약 조성물 | |
| EA038198B1 (ru) | Способы и композиции, в частности, для лечения синдрома дефицита внимания | |
| US9603809B2 (en) | Methods of treatment of attention deficit hyperactivity disorder | |
| JP2008517970A (ja) | 不眠症の治療用薬剤の遅動型投与形態 | |
| US11696895B2 (en) | Fine particle coating (drug-containing hollow particle and method for manufacturing same) | |
| US20240189240A1 (en) | Pharmaceutical compositions comprising zolmitriptan | |
| US20260027063A1 (en) | Compositions for Treatment of Attention Deficit Hyperactivity Disorder | |
| US20070134322A1 (en) | Modified and pulsatile release pharmaceutical formulations of escitalopram | |
| EP2298290A1 (en) | Controlled release composition comprising levetiracetam | |
| US10905652B2 (en) | Compositions for treatment of attention deficit hyperactivity disorder | |
| CN117750957A (zh) | 包含佐米曲坦的药物组合物 | |
| KR102409102B1 (ko) | 제약 조성물 | |
| KR20230129433A (ko) | 피리도스티그민을 포함하는 연장된 방출 조성물 | |
| HK40097882A (zh) | 包含吡斯的明的延长释放组合物 | |
| AMITRIPTYLINE | in partial fulfilment of the requirements for the award of degree of MASTER OF PHARMACY IN PHARMACEUTICS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241220 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241220 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241220 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251202 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251202 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260323 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260323 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260323 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260330 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260330 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260330 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260330 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260330 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260330 |